clinical trial · NCT06761976
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
Bayer·—·available
Advanced Non-small Cell Lung CancerCancerSevabertinib
brief summary
The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option.
started
—
primary completion
—
completion
—
last updated
Mar 30, 2026
official title
An Expanded Access Program to Provide Oral Sevabertinib (BAY 2927088) in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring an HER2 (Human Epidermal Growth Factor Receptor 2) Activating Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol